Decision Making in Multiple Sclerosis Care Under Uncertainty
Decision Making in Multiple Sclerosis Care Under Uncertainty
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Quantitative risk
What it measured
Main measures
Therapeutic inertia score
At the completion of the study, an estimated 90 minutes
Accuracy of treatment decisions
At the completion of the study, an estimated 90 minutes
Other measures (3)
Therapeutic decisions under fatigue
At the completion of the study, an estimated 90 minutes
FatiguePrevalence of therapeutic inertia (TI)
At the completion of the study, an estimated 90 minutes
Factors associated with therapeutic decisions
At the completion of the study, an estimated 90 minutes
Who could take part
MS (type not specified) · 23 to 80
Show the full criteria
Inclusion criteria
* Actively practicing neurologist * Expertise in treating patients with multiple sclerosis (at least 12 per year) * Clinical setting: academic or community institutions, private practice or outpatient clinic * Certified physicians in their specialty * Online consent to participate in the study
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The main objectives of this study are: i) To determine patient-level, physician-level and health system factors influencing therapeutic decisions in multiple sclerosis (MS) care by applying conjoint discrete experiments. ii) To determine the prevalence of therapeutic inertia among participating neurologists. iii) To compare clinical judgement vs. a qualitative or quantitative approach when assessing for a given case-scenario. iv) To evaluate the influence of decision fatigue in treatment decisions.
Papers
Loading reviews and guidelines…
History
Started
Jul 2019
Main results due
Jul 2021
Finished
Dec 2021